Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Division of Nephrology, Department of Internal Medicine, Dr. Lutfi Kirdar Kartal Teaching and Research Hospital, Istanbul, Turkey.
Int Urol Nephrol. 2021 Oct;53(10):2117-2125. doi: 10.1007/s11255-021-02783-0. Epub 2021 Feb 6.
The prognostic factors for COVID-19 in patients with chronic kidney disease (CKD) are uncertain. We conducted a study to compare clinical and prognostic features between hospitalized COVID-19 patients with and without CKD.
Fifty-six patients with stage 3-5 CKD and propensity score-matched fifty-six patients without CKD were included in the study. Patients were followed-up at least fifteen days or until death after COVID-19 diagnosis. The endpoints were death from all causes, development of acute kidney injury (AKI) or cytokine release syndrome or respiratory failure, or admission to the intensive care unit (ICU).
All patients were reviewed retrospectively over a median follow-up of 44 days (IQR, 36-52) after diagnosis of COVID-19. Patients with CKD had higher intensive care unit admission and mortality rates than the patients without CKD, but these results did not reach statistical significance (16 vs. 19; p = 0.54 and 11 vs. 16, p = 0.269, respectively). The frequency of AKI development was significantly higher in predialysis patients with CKD compared to the other group (8 vs. 5; p < 0.001), but there was no significant difference between the groups in terms of cytokine release syndrome (13 vs. 8; p = 0.226), follow-up in the ICU (19 vs. 16; p = 0.541), and respiratory failure (25 vs. 22, p = 0.566). Multivariate logistic regression analysis revealed that respiratory failure and AKI were independent risk factors for mortality.
The mortality rates of COVID-19 patients with CKD had higher than COVID-19 patients without CKD. Also, AKI and respiratory failure were independently related to mortality.
COVID-19 合并慢性肾脏病(CKD)患者的预后因素尚不确定。本研究旨在比较住院 COVID-19 患者合并和不合并 CKD 的临床和预后特征。
本研究纳入 56 例 CKD 3-5 期患者和 56 例匹配的无 CKD 患者。对患者进行至少 15 天或 COVID-19 确诊后至死亡或发生急性肾损伤(AKI)、细胞因子释放综合征或呼吸衰竭、入住重症监护病房(ICU)的随访。
所有患者均在 COVID-19 确诊后中位随访 44 天(IQR,36-52)时进行回顾性分析。与无 CKD 患者相比,CKD 患者 ICU 入住率和死亡率更高,但无统计学意义(16 例 vs. 19 例;p=0.54 和 11 例 vs. 16 例;p=0.269)。与其他组相比,CKD 未透析患者 AKI 发生率明显更高(8 例 vs. 5 例;p<0.001),但细胞因子释放综合征(13 例 vs. 8 例;p=0.226)、ICU 随访(19 例 vs. 16 例;p=0.541)和呼吸衰竭(25 例 vs. 22 例;p=0.566)差异无统计学意义。多因素逻辑回归分析显示,呼吸衰竭和 AKI 是死亡的独立危险因素。
COVID-19 合并 CKD 患者的死亡率高于 COVID-19 不合并 CKD 患者。此外,AKI 和呼吸衰竭与死亡率独立相关。